Cash Flow from Financial Activities: The net amount of cash transactions used in funding activities.
Provectus Biopharmaceuticals, Inc. (PVCT) had Cash Flow from Financial Activities of $1.62M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-0.98M |
|
-- |
|
-- |
|
$0.94M |
|
$-0.94M |
|
$-0.05M |
|
$-0.99M |
|
$-0.99M |
|
$-0.99M |
|
$-0.99M |
|
$-0.99M |
|
$-0.99M |
|
$-0.94M |
|
$-0.94M |
|
420.28M |
|
420.28M |
|
$0.00 |
|
$0.00 |
|
| Balance Sheet Financials | |
$1.37M |
|
$0.00M |
|
$0.10M |
|
$1.47M |
|
$7.71M |
|
-- |
|
$0.05M |
|
$7.76M |
|
$-6.30M |
|
$-6.29M |
|
$-6.29M |
|
420.28M |
|
| Cash Flow Statement Financials | |
$-0.72M |
|
-- |
|
|
Cash Flow from Financial Activities |
$1.62M |
$0.25M |
|
$1.16M |
|
$0.91M |
|
$0.61M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.18 |
|
-- |
|
-- |
|
-- |
|
-0.54 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-0.72M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
15.69% |
|
15.72% |
|
-67.10% |
|
15.72% |
|
$-0.01 |
|
$-0.00 |
|
$-0.00 |
|